Second-line liposomal irinotecan plus fluorouracil and leucovorin in metastatic biliary tract cancer

In The Lancet Oncology, Changhoon Yoo and colleagues1 reported the results of the NIFTY trial, a multicentre, open-label, randomised, phase 2b study done in five academic institutions in South Korea to assess the efficacy of second-line liposomal irinotecan plus fluorouracil and leucovorin in patients with metastatic biliary tract cancer who had progressed on gemcitabine plus cisplatin. Patients treated with liposomal irinotecan plus fluorouracil and leucovorin showed a significant increase in median progression-free survival (7·1 months, 95% CI 3·6–8·8) compared with patients treated with fluorouracil and leucovorin alone (1·4 months, 95% CI 1·2–1·5; hazard ratio 0·56, 95% CI 0·39–0·81; p=0·0019).